Moxonidine-SZ, 0.4 mg 30 pcs

An antihypertensive drug with a central mechanism of action.

In brain stem structures (rostral layer of lateral ventricles) moxonidine selectively stimulates imidazoline-sensitive receptors participating in tonic and reflex regulation of sympathetic nervous system.

Stimulation of imidazoline receptors reduces peripheral sympathetic activity and BP.

Moxonidine differs from other sympatholytic antihypertensive agents in its lower affinity for α2-adrenoreceptors, which explains the lower likelihood of developing sedation and dry mouth.

The use of moxonidine leads to a decrease in ROS and BP.

Moxonidine improves insulin sensitivity index by 21% (compared to placebo) in patients with obesity, insulin resistance and moderate arterial hypertension.

Indications

Arterial hypertension.

Active ingredient

Moxonidine

Composition

1 tablet. – moxonidine 0.4 mg.

How to take, the dosage

The drug is taken orally, regardless of meals.

Interaction

The co-administration of moxonidine with other antihypertensive agents leads to additive effects.

Tricyclic antidepressants may decrease the effectiveness of central antihypertensive agents, and therefore their simultaneous use with moxonidine is not recommended.

Moxonidine may increase the effect of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics. Moxonidine may moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may increase the sedative effect of benzodiazepine derivatives when used concomitantly.

Moxonidine is excreted by tubular secretion, therefore interaction with other drugs excreted by tubular secretion cannot be excluded.

Beta-adrenoblockers increase bradycardia, the severity of negative and dromotropic effects.

Special Instructions

If it is necessary to withdraw beta-adrenoblockers and Moxonidine-SZ taken simultaneously, the beta-adrenoblockers should be withdrawn first and only after several days Moxonidine-SZ. There is currently no evidence that discontinuation of Moxonidine-SZ leads to an increase in BP. However, it is not recommended that Moxonidine-SZ be stopped abruptly; instead, the dose should be gradually reduced over 2 weeks.

Alcohol should be avoided during treatment.

During treatment, regular monitoring of HR and ECG is necessary.

The effect of Moxonidine-SZ on the ability to drive vehicles and operate machinery

The effect of Moxonidine-SZ on the ability to drive vehicles or operate machinery has not been studied.

Because of the possibility of dizziness and somnolence, however, patients should be cautious when driving vehicles and engaging in other activities requiring increased concentration.

Contraindications

– severe renal failure (CKR less than 30 ml/min);

– marked cardiac rhythm disturbances;

– CCS;

– marked bradycardia (resting heart rate less than 50 beats/min).

– AV-blockade of II and III degree;

– acute and chronic heart failure (functional class III-IV according to NYHA classification);

– concomitant use with tricyclic antidepressants;

– hemodialysis;

– lactation period;

– age older than 75 years;

– age less than 18 years (due to lack of safety and efficacy data);

– hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption;

– hypersensitivity to the active substance and other components of the drug.

Cautions

Particular caution should be exercised when using moxonidine in patients with AV blockade of degree I (risk of bradycardia); severe coronary artery disease, severe CHD or unstable angina (insufficient experience of use), chronic heart failure, severe hepatic insufficiency, renal impairment (CK more than 30 ml/min).

Side effects

The frequency of side effects listed below was determined accordingly as follows: very frequently (>1/10); frequently (>1/100, <1/10); infrequently (>1/1000, <1/100); including individual reports.

CNS disorders: frequent – headache*, dizziness (vertigo), somnolence; infrequent – fainting*.

Psychiatric disorders: often – insomnia; infrequently – nervousness.

Hearing organ and labyrinth disorders: infrequent – tinnitus.

Cardiovascular system: infrequent – significant decrease in BP, orthostatic hypotension*, bradycardia.

Digestive system disorders: very frequently – dry mouth; frequently – diarrhea, nausea, vomiting, dyspepsia.

Skin and subcutaneous tissue: often – skin rash, itching.

Muscular system: often – back pain; infrequently – pain in the neck.

Allergic reactions: infrequent – angioedema.

General disorders and disorders at the site of administration: often – asthenia; infrequently – peripheral edema.

* – frequency is comparable to placebo.

Overdose

There have been reports of several non-fatal overdoses when doses up to 19.6 mg were used at one time.

Symptoms: headache, sedation, excessive BP decrease, dizziness, asthenia, bradycardia, dry mouth, vomiting, increased fatigue, epigastric pain, respiratory depression and impaired consciousness. In addition, transient BP elevation, tachycardia, and hyperglycemia are also possible, as has been shown in several high-dose animal studies.